{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT03792841: Phase 1 Interventional Completed Metastatic Castration-resistant Prostate Cancer
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:efocipegtrutide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04297995: Phase 2 Interventional Active, not recruiting Head and Neck Squamous Cell Carcinoma
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pivekimab sunirine [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04669899: Phase 1/Phase 2 Interventional Completed Cancer
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT03481946: Phase 1 Interventional Completed Hemophilia A; Hemophilia B
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:lorigerlimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03261739: Phase 1 Interventional Completed NAFLD
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03702660: Not Applicable Interventional Completed Type2 Diabetes
(2017)
Source URL:
Class:
PROTEIN
